Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | CELC |
---|---|---|
09:34 ET | 151 | 18.54 |
09:36 ET | 600 | 18.4975 |
09:39 ET | 300 | 18.54 |
09:52 ET | 476 | 18.81 |
09:59 ET | 1494 | 18.54 |
10:03 ET | 100 | 18.48 |
10:06 ET | 601 | 18.415 |
10:08 ET | 100 | 18.41 |
10:10 ET | 100 | 18.39 |
10:15 ET | 1204 | 18.445 |
10:19 ET | 408 | 18.39 |
10:21 ET | 100 | 18.385 |
10:24 ET | 163348 | 18.25 |
10:26 ET | 400 | 18.17 |
10:28 ET | 1204 | 18.26 |
10:32 ET | 3416 | 18.28 |
10:33 ET | 1200 | 18.22 |
10:37 ET | 200 | 18.22 |
10:39 ET | 100 | 18.14 |
10:44 ET | 100 | 18.15 |
10:46 ET | 225 | 18.16 |
10:48 ET | 100 | 18.2 |
10:51 ET | 425 | 18.15 |
10:55 ET | 100 | 18.23 |
10:57 ET | 425 | 18.15 |
11:00 ET | 100 | 18.19 |
11:02 ET | 1175 | 18.15 |
11:04 ET | 500 | 18.12 |
11:06 ET | 1409 | 18.12 |
11:11 ET | 1122 | 17.98 |
11:13 ET | 1273 | 18.005 |
11:18 ET | 1300 | 18.07 |
11:20 ET | 5316 | 18.165 |
11:22 ET | 324 | 18.15 |
11:24 ET | 350 | 18.12 |
11:31 ET | 1000 | 18 |
11:33 ET | 618 | 17.92 |
11:36 ET | 1304 | 17.9275 |
11:38 ET | 100 | 17.95 |
11:40 ET | 200 | 17.91 |
11:42 ET | 100 | 17.92 |
11:44 ET | 600 | 17.88 |
11:45 ET | 1573 | 17.86 |
11:47 ET | 200 | 17.83 |
11:49 ET | 500 | 17.86 |
11:51 ET | 100 | 17.85 |
11:56 ET | 11329 | 17.8 |
11:58 ET | 2321 | 17.91 |
12:00 ET | 32428 | 17.9 |
12:02 ET | 100 | 17.94 |
12:03 ET | 300 | 17.9 |
12:05 ET | 600 | 17.975 |
12:16 ET | 700 | 17.92 |
12:20 ET | 1736 | 18.0675 |
12:25 ET | 1000 | 18 |
12:30 ET | 200 | 17.9 |
12:32 ET | 418 | 17.973 |
12:34 ET | 100 | 17.955 |
12:38 ET | 300 | 17.91 |
12:41 ET | 100 | 17.91 |
12:43 ET | 500 | 17.91 |
12:48 ET | 414 | 17.905 |
12:50 ET | 100 | 17.905 |
12:52 ET | 100 | 17.905 |
12:56 ET | 2300 | 17.92 |
01:01 ET | 155 | 17.9855 |
01:06 ET | 180 | 17.93 |
01:24 ET | 451 | 17.995 |
01:26 ET | 400 | 17.995 |
01:33 ET | 371 | 18.08 |
01:35 ET | 1197 | 17.99 |
01:37 ET | 100 | 17.99 |
01:42 ET | 115 | 18.0599 |
01:48 ET | 111 | 17.99 |
02:02 ET | 200 | 18.06 |
02:06 ET | 4120 | 18.06 |
02:08 ET | 200 | 18.055 |
02:11 ET | 400 | 18.065 |
02:13 ET | 600 | 18.075 |
02:15 ET | 1441 | 18.05 |
02:18 ET | 900 | 18.06 |
02:20 ET | 200 | 18.04 |
02:26 ET | 1591 | 18 |
02:27 ET | 144 | 18 |
02:29 ET | 100 | 17.99 |
02:38 ET | 500 | 17.94 |
02:40 ET | 530 | 18.005 |
02:42 ET | 452 | 17.97 |
02:44 ET | 100 | 18.01 |
02:54 ET | 148 | 17.997 |
02:56 ET | 200 | 18.02 |
02:58 ET | 100 | 18.04 |
03:00 ET | 1509 | 17.985 |
03:02 ET | 100 | 17.985 |
03:03 ET | 800 | 17.96 |
03:05 ET | 230 | 17.96 |
03:09 ET | 1151 | 18.03 |
03:12 ET | 200 | 18.005 |
03:16 ET | 1010 | 18.0345 |
03:20 ET | 800 | 17.97 |
03:23 ET | 1144 | 18.08 |
03:32 ET | 1200 | 18.13 |
03:38 ET | 575 | 18.2 |
03:39 ET | 604 | 18.245 |
03:41 ET | 1413 | 18.22 |
03:43 ET | 100 | 18.24 |
03:45 ET | 100 | 18.23 |
03:48 ET | 2022 | 18.28 |
03:50 ET | 2023 | 18.31 |
03:52 ET | 1700 | 18.22 |
03:54 ET | 2451 | 18.17 |
03:56 ET | 1300 | 18.22 |
03:57 ET | 2248 | 18.18 |
03:59 ET | 3600 | 18.17 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Celcuity Inc | 656.0M | -6.5x | --- |
Kalvista Pharmaceuticals Inc | 651.7M | -4.4x | --- |
Astria Therapeutics Inc | 650.2M | -4.9x | --- |
Cassava Sciences Inc | 649.1M | -8.2x | --- |
Arrivent Biopharma Inc | 663.8M | 0.0x | --- |
Corbus Pharmaceuticals Holdings Inc | 644.2M | -8.5x | --- |
Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a potent, small molecule reversible inhibitor, that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic target of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its initial clinical development programs for gedatolisib are focusing on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. Its VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells to identify new groups of cancer patients.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $656.0M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 35.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.82 |
EPS | $-2.79 |
Book Value | $5.48 |
P/E Ratio | -6.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.